Memantine prevents the cognitive impairment induced by 3,4-methylenedioxymethamphetamine in rats

European Journal of Pharmacology

Volumn 589, Issue 1-3, 2008, Pages 132-139

  Camarasa, Jorge ^a   Marimón, José M ^a   Rodrigo, Teresa ^a   Escubedo, Elena ^a   Pubill, David ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Ecstasy; Learning and memory; MDMA; Memantine; Morris water maze; Object recognition

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; AMPHETAMINE; AMPHETAMINE DERIVATIVE; BUNGAROTOXIN RECEPTOR; BUNGAROTOXIN RECEPTOR ANTAGONIST; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NICOTINIC RECEPTOR BLOCKING AGENT; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DRUG DEPENDENCE TREATMENT; DRUG EFFICACY; LEARNING; MALE; MAZE TEST; MEMORY; MEMORY DISORDER; MORRIS WATER MAZE TEST; MOUSE; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT; REARING; SINGLE DRUG DOSE; SPATIAL MEMORY; SWIMMING; TREATMENT OUTCOME; VISUAL MEMORY;

3,4-METHYLENEDIOXYAMPHETAMINE; ANIMALS; BEHAVIOR, ANIMAL; CENTRAL NERVOUS SYSTEM STIMULANTS; COGNITION; COGNITION DISORDERS; DISCRIMINATION (PSYCHOLOGY); DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID ANTAGONISTS; EXPLORATORY BEHAVIOR; MALE; MAZE LEARNING; MEMANTINE; MICE; MOTOR ACTIVITY; NICOTINIC ANTAGONISTS; RATS; RATS, LONG-EVANS; RECOGNITION (PSYCHOLOGY); TIME FACTORS;

EID: 47549091505     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.05.014     Document Type: Article

References (61)

1. Abi-Saab W.M., DeSouza D.C., Moghaddam B., and Krystal J.H. The NMDA antagonist model for schizophrenia: promise and pitfalls. Pharmacopsychiatry 31 (1998) 104-109
2. Aggleton J.P. One-trial object-recognition by rats. Q. J. Exp. Psychol. 37 (1985) 279-294
3. Aracava Y., Pereira E.F., Maelicke A., and Albuquerque E.X. Memantine blocks alpha7 nicotinic acetylcholine receptors more potently than n-methyl-D-aspartate receptors in rat hippocampal neurons. J. Pharmacol. Exp. Ther. 313 (2005) 928-929
4. Barnes C.A., Danysz W., and Parsons C.G. Effects of the uncompetitive NMDA receptor antagonist memantine on hippocampal long-term potentiation, short-term exploratory modulation and spatial memory in awake, freely moving rats. Eur. J. Neurosci. 8 (1996) 565-571
5. Barnett S.A., and Cowan P.E. Activity, exploration, curiosity and fear: an ethological study. Interdiscip. Sci. Rev. 1 (1976) 43-62
6. Bisagno V., Ferguson D., and Luine V.N. Short toxic methamphetamine schedule impairs object recognition task in male rats. Brain Res. 940 (2002) 95-101
7. Bolla K.I., McCann U.D., and Ricaurte G.A. Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology 51 (1998) 1532-1537
8. Brandeis R., Brandys Y., and Yehuda S. The use of the Morris water maze in the study of memory and learning. Int. J. Neurosci. 48 (1989) 26-29
9. Cain D.P., Saucier D., Hall J., Hargreaves E.L., and Boon F. Detailed behavioural analysis of water maze acquisition under APV or CNQX: contribution of sensorimotor disturbances to drug-induced acquisition deficits. Behav. Neurosci. 110 (1996) 86-102
10. Callaway C.W., Wing L.L., and Geyer M.A. Serotonin release contributes to the locomotor stimulant effects of 3,4-methylenedioxymethamphetamine in rats. J. Pharmacol. Exp. Ther. 254 (1990) 456-464
11. Chipana C., Camarasa J., Pubill D., and Escubedo E. Protection against MDMA-induced dopaminergic neurotoxicity in mice by methyllycaconitine: involvement of nicotinic receptors. Neuropharmacology 51 (2006) 885-895
12. Chipana C., Camarasa J., Pubill D., and Escubedo E. Memantine prevents MDMA-induced neurotoxicity. Neurotoxicology 29 (2008) 179-183
13. Chipana C., García-Ratés S., Camarasa J., Pubill D., and Escubedo E. Different oxidative profile and nicotinic receptor interaction of amphetamine and 3,4-methylenedioxy-methamphetamine. Neurochem. Int. 52 (2008) 401-410
14. De Micheli D., and Formigoni M.L. Drug use by Brazilian students: associations with family, psychosocial, health, demographic and behavioral characteristics. Addiction 99 (2004) 570-578
15. De Souza E.B., Battaglia G., and Insel T.R. Neurotoxic effect of MDMA on brain serotonin neurons: evidence from neurochemical and radioligand binding studies. Ann. N.Y. Acad. Sci. 600 (1990) 682-697
16. Dineley K.T., Bell K.A., Bui D., and Sweatt J.D. Beta-amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol. Chem. 277 (2002) 25056-25061
17. Dix S.L., and Aggleton J.P. Extending the spontaneous preference test of recognition: evidence of object-location and object-context recognition. Behav. Brain Res. 99 (1999) 191-200
18. Ennanceur A., and Delacour J. A new one-trial test for neurobiological studies of memory in rats 1: behavioural data. Behav. Brain Res. 31 (1988) 47-59
19. Escubedo E., Guitart L., Sureda F.X., Jimenez A., Pubill D., Pallas M., Camins A., and Camarasa J. Microgliosis and down-regulation of adenosine transporter induced by methamphetamine in rats. Brain Res. 814 (1998) 120-126
20. Escubedo E., Chipana C., Pérez-Sánchez M., Camarasa J., and Pubill D. Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum: Involvement of alpha7 nicotinic receptors. J. Pharmacol. Exp. Ther. 315 (2005) 658-667
21. French E.D., Ferkany J., Abreu M., and Levenson S. Effects of competitive N-methyl-D-aspartate antagonists on midbrain dopamine neurons: an electrophysiological and behavioral comparison to phencyclidine. Neuropharmacology 30 (1991) 1039-1046
22. Garcia-Ratés S., Camarasa J., Escubedo E., and Pubill D. Methamphetamine and 3,4-methylenedioxymethamphetamine interact with central nicotinic receptors and induce their up-regulation. Toxicol. Appl. Pharmacol. 223 (2007) 195-205
23. Gerra G., Zaimovic A., Ferri M., Zambelli U., Timpano M., Neri E., Marzocchi G.F., Delsignore R., and Brambilla F. Long-lasting effects of (±)3,4-methylene-dioxymethamphetamine (ecstasy) on serotonin system function in humans. Biol. Psychiatr. 47 (2000) 127-136
24. Gibb J.W., Johnson M., and Hanson G.R. Neurochemical basis of neurotoxicity. Neurotoxicology 11 (1990) 317-321
25. Gouzoulis-Mayfrank E., Daumann J., Tuchtenhagen F., Pelz S., Becker S., Kunert H.J., Fimm B., and Sass H. Impaired cognitive performance in drug free users of recreational ecstasy (MDMA). J. Neurol. Neurosurg. Psychiatr. 68 (2000) 719-725
26. Green A.R., Mechan A.O., Elliott J.M., O'Shea E., and Colado M.I. The pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy"). Pharmacol. Rev, 55 (2003) 463-508
27. Hargreaves E.L., and Cain D.P. MK801-induced hyperactivity: duration of effects in rats. Pharmacol. Biochem. Behav. 51 (1995) 13-19
28. Irvine R.J., Keane M., Felgate P., McCann U.D., Callaghan P.D., and White J.M. Plasma drug concentrations and physiological measures in 'dance party' participants. Neuropsychopharmacology 31 (2006) 424-430
29. Klingler W., Heffron J.J., Jurkat-Rott K., O'sullivan G., Alt A., Schlesinger F., Bufler J., and Lehmann-Horn F. 3,4-Methylenedioxymethamphetamine (ecstasy) activates skeletal muscle nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 314 (2005) 1267-1273
30. Kouimtsidis C., Schifano F., Sharp T., Ford L., Robinson J., and Magee C. Neurological and psychopathological sequelae associated with a lifetime intake of 40,000 ecstasy tablets. Psychosomatics 47 (2006) 86-87
31. Krebs K.M., and Geyer M.A. Behavioral characterization of alpha-ethyltryptamine, a tryptamine derivative with MDMA-like properties in rats. Psychopharmacology (Berl). 113 (1993) 284-287
32. Levi M.S., and Borne R.F. A review of chemical agents in the pharmacotherapy of addiction. Curr. Med. Chem. 9 (2002) 1807-1818
33. Lieb R., Schuetz C.G., Pfister H., Sydow K., and Wittchen H.U. Mental disorders in ecstasy users: a prospective-longitudinal Investigation. Drug Alcohol Depend. 68 (2002) 95-207
34. McCann U.D., Mertl M., Eligulashvili V., and Ricaurte G.A. Cognitive performance in (+/-) 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") users: a controlled study. Psychopharmacology (Berl). 143 (1999) 417-425
35. Misztal M., and Danysz W. Comparison of glutamate antagonists in continuous multiple-trial and single-trial dark avoidance. Behav. Pharmacol. 6 (1995) 550-561
36. Mordenti J., and Chappell W. The use of interspecies scaling in toxicokinetics. In: Yacobi A., Kelly J., and Batra V. (Eds). Toxicokinetics in New Drug Development (1989), Pergamon, New York 42-96
37. Morgan M.J. Ecstasy (MDMA): a review of its persistent psychological effects. Psychopharmacology 152 (2000) 230-248
38. Morley K.C., Gallate J.E., Hunt G.E., Mallet P.E., and McGregor I.S. Increased anxiety and impaired memory in rats 3 months after administration of 3,4-methylenedioxymethamphetamine ("Ecstasy"). Eur. J. Pharmacol. 433 (2001) 91-99
39. Morris R.G.M., Garrud P., Rawlins J.N.P., and O'Keefe J. Place navigation impaired in rats with hippocampal lesions. Nature 297 (1982) 681-683
40. Nichols D.E., and Oberlender R. Structure-activity relationships of MDMA and related compounds: a new class of psychoactive drugs. Ann. N.Y. Acad. Sci. 600 (1990) 613-623
41. Nordberg A. Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications. Biol. Psychiatr. 49 (2001) 200-210
42. Pubill D., Canudas A.M., Pallas M., Camins A., Camarasa J., and Escubedo E. Different glial response to methamphetamine- and methylenedioxymethamphetamine-induced neurotoxicity. Naunyn Schmiedeberg's Arch. Pharmacol. 367 (2003) 490-499
43. Pubill D., Chipana C., Camins A., Pallàs M., Camarasa J., and Escubedo E. Free radical production induced by methamphetamine in rat striatal synaptosomes. Toxicol. Appl. Pharmacol. 204 (2005) 57-68
44. Rammes G., Rupprecht R., Ferrari U., Zieglgansberger W., and Parsons C.G. The N-methyl-D-aspartate receptor channel blockers memantine, MRZ 2/579 and other amino-alkyl-cyclohexanes antagonise 5-HT(3) receptor currents in cultured HEK-293 and N1E-115 cell systems in a non-competitive manner. Neurosci. Lett. 306 (2001) 81-84
45. Rampon C., Tang Y.P., Goodhouse J., Shimizu E., Kyin M., and Tsien J.Z. Enrichment induces structural changes and recovery from nonspatial memory deficits in CA1 NMDAR1-knockout mice. Nat. Neurosci. 3 (2000) 238-244
46. Reed J.M., and Squire L.R. Impaired recognition memory in patients with lesions limited to the hippocampal formation. Behav. Neurosci. 111 (1997) 667-675
47. Ricaurte G.A., Markowska A.L., Wenk G.L., Hatzidimitriou G., and Wlos J. 3,4-Methylenedioxymethamphetamine, serotonin, and memory. J. Pharmacol. Exp. Ther. 266 (1993) 1097-1105
48. Ricaurte G.A., Yuan J., and McCann U.D. (+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: studies in animals. Neuropsychobiology 42 (2000) 5-10
49. Rodgers J., Buchanan T., Scholey A.B., Heffernan T.M., Ling J., and Parrott A.C. Patterns of drug use and the influence of gender on self-reports of memory ability in ecstasy users: a web-based study. J. Psychopharmacol. 17 (2003) 389-396
50. Rogawski M.A. Low affinity channel blocking (uncompetitive) NMDA receptor antagonists as therapeutic agents: toward an understanding of their favourable tolerability. Amino Acids 19 (2000) 133-149
51. Rogers R.D., Everitt B.J., Baldacchino A., Blackshaw A.J., Swainson R., Wynne K., Baker N.B., Hunter J., Carthy T., Booker E., London M., Deakin J.F., Sahakian B.J., and Robbins T.W. Dissociable deficits in the decision-making cognition of chronic amphetamine abusers, opiate abusers, patients with focal damage to prefrontal cortex, and tryptophan-depleted normal volunteers: evidence for monoaminergic mechanisms. Neuropsychopharmacology 20 (1999) 322-339
52. Schifano F., Di Furia L., Forza G., Minicuci N., and Bricolo R. MDMA ('ecstasy') consumption in the context of polydrug abuse: a report on 150 patients. Drug Alcohol Depend. 52 (1998) 85-90
53. Scholey A.B., Parrott A.C., Buchanan T., Heffernan T.M., Ling J., and Rodgers J. Increased intensity of ecstasy and polydrug usage in the more experienced recreational ecstasy/MDMA users: a WWW study. Addict. Behav. 29 (2004) 743-752
54. Simon S.L., Domier C.P., Sim T., Richardson K., Rawson R.A., and Ling W. Cognitive performance of current methamphetamine and cocaine abusers. J. Addict. Res. 21 (2002) 61-74
55. Tariot P.N., Farlow M.R., Grossberg G.T., Graham S.M., McDonald S., and Gergel I. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. J. Am. Med. Assoc. 291 (2004) 317-324
56. Verkes R.J., Gijsman H.J., and Pieters M.S. Cognitive performance and serotonergic function in users of ecstasy. Psychopharmacology 153 (2001) 196-202
57. Wenk G.L., Zajaczkowski W., Danysz W., and Quack G. Neuroprotection of acetylcholinergic basal forebrain neurons by memantine and neurokinin B infusion of (±)-MK-801 and memantine: contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Behav. Brain Res. 83 (1997) 129-133
58. Wolfer D.P., Madani R., Valenti P., and Lipp H.P. Extended analysis of path data from mutant mice using the public domain software Wintrack. Physiol. Behav. 73 (2001) 745-753
59. Yamamoto B.K., Nash J.F., and Gudelsky G.A. Modulation of methylenedioxymethamphetamine-induced striatal dopamine release by the interaction between serotonin and gamma-aminobutyric acid in the substantia nigra. J. Pharmacol. Exp. Ther. 273 (1995) 1063-1070
60. Zajaczkowski W., Quack G., and Danysz W. Infusion of (±)-MK-801 and memantine: contrasting effects on radial maze learning in rats with entorhinal cortex lesion. Eur. J. Pharmacol. 296 (1996) 239-246
61. Zakzanis K.K., and Young D.A. Memory impairment in abstinent MDMA ("Ecstasy") users: a longitudinal investigation. Neurology 56 (2001) 966-969